Enanta Pharmaceuticals Inc (ENTA)

[dewophile]

Coverage for neonates and infants was already pretty good between Beyfortus and maternal vaccination at somewhere in the 80 percent range. This might push it a tad higher who knows
I don’t think it’s clear yet if expanded infant passive immunity is good or bad or neutral for a pediatric antiviral. My guess is a tad negative because older infants and children who get a first RSV infection are less likely to probably require medical intervention because of more mature immune systems in general. However this may be partly or wholly offset (and then some) by the need for higher drug doses in those kids who do require antiviral because you are skewing the age of first infection upward and the bigger the kid the more drug per course you need